Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation

Blood

Volumn 112, Issue 5, 2008, Pages 2120-2128

  Mullighan, Charles G ^a,c   Heatley, Susan L ^b   Danner, Silke ^b   Dean, Melinda M ^b   Doherty, Kathleen ^b   Hahn, Uwe ^a   Bradstock, Kenneth F ^d   Minchinton, Robyn ^b   Schwarer, Anthony P ^e   Szer, Jeff ^f   Bardy, Peter G ^a,b,g  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d WESTMEAD HOSPITAL   (Australia)

^e ALFRED HOSPITAL   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; FLUDARABINE; FOSCARNET; GANCICLOVIR; LOMUSTINE; MANNOSE BINDING LECTIN 2; MELPHALAN; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORFLOXACIN; STEROID; TACROLIMUS; MANNOSE BINDING LECTIN; MBL2 PROTEIN, HUMAN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GENE MUTATION; GENOTYPE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INCIDENCE; INFECTION RISK; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELOABLATIVE CONDITIONING; ORGAN DONOR; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SEPSIS; SIBLING; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; BLOOD; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFECTION; MIDDLE AGED; MISSENSE MUTATION; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; FEMALE; GENOTYPE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; MALE; MANNOSE-BINDING LECTIN; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RISK FACTORS; SIBLINGS; TRANSPLANTATION, HOMOLOGOUS;

EID: 52649118504     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-07-100222     Document Type: Article

References (21)

1. Worthley DL, Bardy PG, Mullighan CG. Mannosebinding lectin: biology and clinical implications. Intern Med J. 2005;35:548-555.
2. Minchinton RM, Dean MM. ClarkTR, Heatley S, Mullighan CG. Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an Australian blood donor population. Scand J Immunol. 2002;56:630-641.
3. Lipscombe RJ, Beatty DW, Ganczakowski M, et al. Mutations in the human mannose-binding protein gene: frequencies in several population groups. Eur J Human Genet. 1996:4:13-19.
4. Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding lectin deficiency: revisited. Mol Immunol. 2003;40:73-84.
5. Madsen HO, Garred P, Thiel S, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol. 1995;155:3013-3020.
6. Peterslund NA, Koch C, Jensenius JC, Thiel S. Association between deficiency of mannosebinding lectin and severe infections after chemotherapy. Lancet. 2001;358:637-638.
7. Neth O, Hann I, Turner MW. Klein NJ. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet. 2001;358:614-618.
8. Molle I, Steffensen R, Thiel S, Peterslund NA. Chemotherapy-related infections in patients with multiple myeloma: associations with mannanbinding lectin genotypes. Eur J Haematol. 2006; 77:19-26.
9. Molle I, Peterslund NA, Thiel S, Steffensen R. MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant. 2006; 38:555-560.
10. Mullighan CG, Heatley S, Doherty K, et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood. 2002;99:3524-3529.
11. Rocha V. Franco RF, Porcher R. et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood. 2002; 100:3908-3918.
12. Granell M. Urbano-lspizua A, Suarez B, et al. Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol. 2006;34: 1435-1441.
13. Mullighan CG, Marshall SE, Welsh Kl. Mannose binding lectin polymorphisms are associated with early age of disease onset and autoimmunity in common variable immunodeficiency. Scand J Immunol. 2000;51:111-122.
14. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
15. Fine JP, Gray RJ. Aproportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
16. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant. 2007;40:381-387.
17. Valdimarsson H. Stefansson M, Vikingsdottir T. et al. Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans. Scand J Immunol. 1998;48: 116-123.
18. Shank B, Hoppe RT. Radiotherapeutic principles of hematopoietic cell transplantation. In: Blume KG, Forman SJ, appelbaum FR, eds. Thomas' Hematopoietic Gell Transplantation. Maiden, MA: Blackwell Publishing; 2004:178-197.
19. Wingard JR. Leather HL. Bacterial Infections. In: Blume KG, Forman SJ, appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation. Maiden, MA: Blackwell Publishing; 2004:665-682.
20. Ezekowitz RA, Day LE. Herman GA. A human mannose-binding protein is an acute-phase reactant that shares sequence homology with other vertebrate lectins. J Exp Med. 1988;167:1034-1046.
21. Kilpatrick DC, Stewart K, Allan EK, McLintock LA, Holyoake TL, Turner ML. Successful haemopoietic stem cell transplantation does not correct mannan-binding lectin deficiency. Bone Marrow Transplant. 2005;35:179-181.